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Is beta-radiation better than 5 flurouracil as an adjunct for
trabeculectomy surgery when combined with cataract surgery?
Summary
Glaucoma is the second most common cause of blindness in the world after cataract.
Many patients with glaucoma also have some cataract. In an African context, if the
cataract does not cause significant disability it would not normally warrant surgical
intervention. Removal of the cataract would, none-the-less offer brighter vision and
saves them surgery at a later date.
Because of the high prevalence of co-pathology (cataract and glaucoma) in our
population, and also the frequency of cataract formation following trabeculectomy, we
are performing an increasing number of combined glaucoma and cataract surgeries
(usually combined phaco-emulsification and trabeculectomy with 5FU augmentation)
and have reported our short term outcomes. Performing cataract surgery at the
same time as glaucoma surgery conveys the potential advantages of saving the
patient an extra operation or preventing sight loss from cataract if the patient defaults
from follow up. Doing cataract surgery at the same time as the glaucoma surgery,
however, has disadvantages. The major cause of failure in this surgery is post-
operative scaring which seals the drainage fistula
Current best practice in many African Eye Units is to use adjunctive 5 fluorouracil at
the time of surgery in order to inhibit this scarring response. The evidence base for
major effectiveness of this therapy is not overwhelming. Our group have completed a
randomised controlled trial of beta-radiation for trabeculectomy compared to placebo
and demonstrated a striking beneficial effect. This new study is to undertake a
comparison of beta-radiation with 5 fluorouracil in order to inform current best
practice and to investigate if improved success can be offered with this alternative
anti-scarring therapy in combined cataract and drainage surgery.
Introduction and literature review
The term glaucoma defines a group of conditions in which there is a characteristic
optic neuropathy associated with visual field loss. Raised intraocular pressure (IOP)
is recognised to be a principal risk factor. The glaucomas are the second most
common cause of blindness in the world.1 2 There are many different types of
glaucoma but about two thirds of global glaucoma is due to primary open angle
glaucoma (POAG). This type of glaucoma is particularly common in Africa 3 4 where
the condition presents earlier in life, often with severe disease.5 6 Because of its
insidious nature, many patients present with total visual loss in at least one eye
already.7 8 We only have one method of treating POAG at present, the lowering of
IOP by medicine or surgery. There is no current method of preventing the onset of
POAG.
In the very small number of studies addressing this issue, drainage surgery has been
demonstrated to give superior long-term therapeutic results in terms of IOP control
and visual field preservation.9 10 POAG in the developing world is characterised by
late presentation with very advanced disease, and by the implausibility of regular
patient assessment.8 Cost, lack of reliable medical supplies and irregular patient
review render medical treatment impractical. It is generally agreed that the treatment
of choice in this setting is primary drainage surgery (trabeculectomy).11
Cataract is the most prevalent cause of blindness globally and is also age-related. It
is therefore not too surprising that patients presenting with glaucoma often have
cataract as co-pathology. The therapy for cataract is cataract extraction with
intraocular lens implantation. In an African context, if the cataract does not cause
significant disability it would not normally warrant surgical intervention. Removal of
the cataract would, none-the-less offer brighter vision and saves them surgery at a
later date. It is well recognized that between 20-50% of those that have
trabeculecotomy surgery alone for glaucoma require subsequent cataract surgery.
Because of the high prevalence of co-pathology (cataract and glaucoma) in our
population, and also the frequency of cataract formation following trabeculectomy, we
are performing an increasing number of combined glaucoma and cataract surgeries
(usually combined phaco-emulsification and trabeculectomy with 5FU augmentation)
and have reported our short term outcomes. Performing cataract surgery at the
same time as glaucoma surgery conveys the potential advantages of saving the
patient an extra operation or preventing sight loss from cataract if the patient defaults
from follow up. Doing cataract surgery at the same time as the glaucoma surgery,
however, has disadvantages. The major cause of failure in this surgery is post-
operative scaring which seals the drainage fistula
Successful trabeculectomy aims at establishing a fistula with continual flow of
aqueous from the anterior chamber to the sub-conjunctival space, from where it is
removed by conjunctival and episcleral blood vessels. The major cause of
trabeculectomy failure is fibrosis in the sub-conjunctival space sealing the fistula.12 13
Most cases of filtration failure have been found to occur within in the first few months
after surgery.14-16 Certain groups of patients have a higher risk of surgical failure,
notably patients with ocular inflammation, those who have received multiple topical
medications, and African and Caribbean patients.17-19 Surgical success rates in
African studies vary enormously between studies, but generally a much lower
success rate has been reported than those in white patients.18 20-22
Probably the most significant change in the technique of glaucoma surgery in the
past 10 years has been the introduction of agents that strongly affect the way
wounds heal. The process of wound healing involves a cascade of cellular and
biochemical events that ultimately results in the formation of a mature scar in the
wound site. For descriptive purposes, this has been divided into an inflammatory, a
proliferative and a remodeling phase, although in-vivo these phases are not distinct.
Modulation of this process can be achieved in several ways. Corticosteroids are used
post-operatively in all operations. Many units in the developed world use the cytotoxic
agents 5-fluorouracil (5FU) and mitomycin C (MMC). These are most frequently
applied at the time of surgery but 5-fluorouracil in particular may be given post-
operatively in addition. Siriwardena and co-workers have recently demonstrated the
use of a recombinent monoclonal antibody against transforming growth factor-beta
(TGF-β) to modulate scarring.29Finally, beta-irradiation has been used.
Beta radiation is a particulate radiation consisting of high-speed electrons of
negligible mass and one negative charge. Because of its low mass, beta radiation is
rapidly attenuated by biological tissues making it very useful for superficial radiation
treatments where deep tissue penetration is undesirable.30 In-vitro cell proliferation
studies have shown that ocular fibroblast proliferation is significantly inhibited by beta
radiation at doses between 500 and 1000 cGy.31 32 The period of growth arrest
persists in-vitro for up to 28 days after doses >500 cGy, with no late recovery in cell
proliferation.33 In addition, these growth arresting doses of radiation do not inhibit
many of the other wound healing functions of the fibroblasts such as migration,
contraction and extracellular matrix deposition, unlike the effects of 5-FU and MMC.
That Beta irradiation reduces wound healing has been known for over sixty years. Its
effects on ocular wound healing have been studied since the 1950’s. The most
common and well-described application has been in the prevention of recurrence
following excision of pterygia. The use of Beta irradiation in glaucoma drainage
surgery was first described in 1944, and has been used on a limited basis since this
time. Beta irradiation augmented trabeculectomy has been shown to provide good
clinical results in congenital glaucoma a condition associated with a high rate of
surgical failure.34 A study in ‘high risk’ eyes demonstrated a clinical effect similar to 5-
FU but with significantly fewer avascular cystic blebs- a potential risk factor for late
infection.35 Beta irradiation is applied at the conclusion of surgery by means of a Beta
irradiation-emitting device. It offers many potential advantages in the treatment of
POAG in the African continent.
1. Once initial capital costs are met the Beta irradiation probe has a life of
approximately twenty years. In the African setting this has enormous
advantages over the ongoing supply costs and logistics of 5FU, MMC and
monoclonal antibodies.
2. Beta irradiation is easy to apply following trabeculectomy surgery. Precautions
to prevent leakage of cytotoxic at the wound site are not required. The probe
does not need sterilisation.
3. Beta irradiation has the longest therapeutic record of any method of
modulation of ocular wound healing. At Moorfields, Beta irradiation has been
used for well over twenty years in both adult and childhood glaucomas. There
is no excess morbidity due to cataract and a very low incidence of bleb related
infection (unlike MMC). The efficacy has, however, never been subject to
scrutiny in a randomised trial with sufficient power.
4. The conjunctival drainage bleb morphology is generally superior, being diffuse
and not thin, cystic and avascular like an MMC bleb and many 5FU blebs.
Because of these very important potential advantages of this form of therapy a large
Wellcome Trust supported trial was undertaken in South Africa. This trial compared
trabeculectomy augmented with 1000 cGy beta radiation with trabeculectomy. There
is very strong evidence that beta radiation reduces substantially the risk of IOP failure
following surgery ( P<0.0001). At one year post-surgery, the estimated risk of failure
was 30% (95% c.i. 22-38%) in the placebo arm compared with 5% (95% c.i. 2-10%)
in the beta radiation arm.
Current ‘best practice’ in Tanzania is considered the use of adjunctive 5 fluorouracil
at the time of surgery. A study is therefore required to assess the relative merits of
these two adjunctive therapies in glaucoma drainage surgery combined with cataract
surgery.
Methods
Design A randomised prospective double blind controlled surgical trial of
trabeculectomy with either per-operative Beta irradiation or 5 fluoro-uracil
augmentation combined with cataract surgery with intraocular lens implantation.
Methods African patients with established primary open angle glaucoma and cataract
requiring trabeculectomy and cataract extraction will be recruited in CCBRT Hospital, Dar
es Salaam, Tanzania. Following randomisation, patients will undergo cataract extraction
with lens implantation combined with trabeculectomy with either exposure to 1000 cGy of
Beta irradiation at the conclusion of surgery with a Strontium-90 containing delivery
device, or 5 minutes sub-conjunctival exposure to 5 fluorouracil by sponge application
with subsequent washout prior to the surgery. Intraocular pressure will be measured at
regular intervals for at least 12 months. The primary outcome measure of the study is
intraocular pressure at 12 months. Secondary outcomes are visual assessment, re
intervention rate, and surgical complications.
Inclusion criteria Exclusion criteria
 Consent to inclusion and participation in trial.
 Characteristic glaucomatous changes in the
optic disc. The presence of a focal or diffuse
area of optic disc rim loss, so that the
neuroretinal rim tissue in any quadrant is less
than 5% of the disc diameter in that meridian.
Extensive loss of neuroretinal rim tissue with
marked optic disc cupping giving a cup disc
ratio greater than 0.8.
 A measured intraocular pressure greater than
or equal to 21 mmHg on at least one visit
before the time of listing for surgery as
measured by Goldmann applanation
tonometry.
 An open angle on gonioscopy
 Cataract sufficient to decrease vision and require
surgical intervention.
 Unwillingness to participate in the study
 Anterior segment neovascularisation
 Past trauma to the eye or ocular adnexae
 Retinal or optic nerve neovascularisation
 Aphakia or pseudophakia
 Previous ocular surgery
 Uveitis
 Inability/unwillingness to give informed consent
 Unwillingness to accept randomisation
 Patient less than 20 years of age
 Pregnancy or female of childbearing age who may be
pregnant at time of treatment (LMP).
 Chronic use of topical or systemic steroids
Patient flow After informed consent all patients undergo a standardised examination
to establish pre-operative ocular function and findings. At the time of surgery the
patient is randomised (blocked (by centre) randomisation in London, contained in
sealed envelopes) to receive beta-radiation or 5 fluorouracil treatment at the time of
cataract surgery and standard trabeculectomy. Every effort will be made to follow all
patients according to a standardised protocol at day 1, week 1 or 2, month 1, month
3, month 6 and month 12. All therapeutic failures will be followed closely to ascertain
further management plans and subsequent therapeutic compliance. Follow-up will be
offered beyond 12 months.
Outcomes The primary outcome is surgical success at twelve months: defined as a
maximum intraocular pressure less than or equal to 21 mmHg as measured using
Goldmann tonometry on no ocular hypotensive therapy. Secondary outcome
variables include visual function, reintervention rate, reintervention acceptance, and
surgical complications.
Sample size Using one eye per patient, this has been calculated using the procedure
described by Altman, calculating the standardised difference for binary data (surgical
success rate). Assuming an estimated improvement of success from 75% to 90%.
For a study with 80% power and using a significance level of 95%, two groups of 112
patients will be required. If loss to follow up of 33% is allowed for, this means that a
total of 298 patients are required.
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